Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Dynamic changes during the treatment of pancreatic cancer.

Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJ.

Oncotarget. 2018 Feb 13;9(19):14764-14790. doi: 10.18632/oncotarget.24483. eCollection 2018 Mar 13.

2.

General Prediction of Peptide-MHC Binding Modes Using Incremental Docking: A Proof of Concept.

Antunes DA, Devaurs D, Moll M, Lizée G, Kavraki LE.

Sci Rep. 2018 Mar 12;8(1):4327. doi: 10.1038/s41598-018-22173-4.

3.

The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.

Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P.

Clin Cancer Res. 2018 Jul 15;24(14):3366-3376. doi: 10.1158/1078-0432.CCR-17-2483. Epub 2018 Mar 1.

PMID:
29496759
4.

Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy.

Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, Lizee GA, Mercado-Uribe I, Baggerly KA, Hwu P, Liu J, Overwijk WW, Coleman RL, Sood AK.

Oncotarget. 2017 Aug 24;8(57):96496-96505. doi: 10.18632/oncotarget.20410. eCollection 2017 Nov 14.

5.

DINC 2.0: A New Protein-Peptide Docking Webserver Using an Incremental Approach.

Antunes DA, Moll M, Devaurs D, Jackson KR, Lizée G, Kavraki LE.

Cancer Res. 2017 Nov 1;77(21):e55-e57. doi: 10.1158/0008-5472.CAN-17-0511.

PMID:
29092940
6.

Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy.

Antunes DA, Rigo MM, Freitas MV, Mendes MFA, Sinigaglia M, Lizée G, Kavraki LE, Selin LK, Cornberg M, Vieira GF.

Front Immunol. 2017 Oct 4;8:1210. doi: 10.3389/fimmu.2017.01210. eCollection 2017.

7.

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes.

Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P.

Nat Commun. 2017 Sep 6;8(1):451. doi: 10.1038/s41467-017-00449-z.

8.

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C.

Cancer Immunol Res. 2017 Aug;5(8):618-629. doi: 10.1158/2326-6066.CIR-17-0051. Epub 2017 Jun 19.

PMID:
28630054
9.

Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy.

Yee C, Lizee GA.

Cancer J. 2017 Mar/Apr;23(2):144-148. doi: 10.1097/PPO.0000000000000255. Review.

PMID:
28410303
10.

Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination.

Li F, Chen C, Ju T, Gao J, Yan J, Wang P, Xu Q, Hwu P, Du X, Lizée G.

Oncoimmunology. 2016 Oct 7;5(12):e1238539. doi: 10.1080/2162402X.2016.1238539. eCollection 2016.

11.

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.

Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, Perakis AA, Becker L, Yoo SY, Dwyer KC, Coombes K, Talukder AH, John LSS, Senyukov V, Lee DA, Sergeeva A, He H, Ma Q, Armistead PM, Roszik J, Mittendorf EA, Molldrem JJ, Hawke D, Lizee G, Kornblau SM.

Leukemia. 2017 Jan;31(1):234-237. doi: 10.1038/leu.2016.249. Epub 2016 Aug 30. No abstract available.

12.

Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome.

Li F, Du X, Zhang H, Ju T, Chen C, Qu Q, Zhang X, Qi L, Lizée G.

Clin Genet. 2017 Mar;91(3):488-493. doi: 10.1111/cge.12809. Epub 2016 Jun 8.

PMID:
27221040
13.

NLRC5/MHC class I transactivator is a target for immune evasion in cancer.

Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):5999-6004. doi: 10.1073/pnas.1602069113. Epub 2016 May 9.

14.

Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma.

Bradley SD, Melendez B, Talukder A, Lizée G.

Oncoimmunology. 2015 Aug 25;5(2):e1078966. eCollection 2016 Feb.

15.

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P.

Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.

16.

Novel Treatments in Development for Melanoma.

Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizée G.

Cancer Treat Res. 2016;167:371-416. doi: 10.1007/978-3-319-22539-5_16. Review.

PMID:
26601872
17.

Endogenous T-Cell Therapy: Clinical Experience.

Yee C, Lizee G, Schueneman AJ.

Cancer J. 2015 Nov-Dec;21(6):492-500. doi: 10.1097/PPO.0000000000000158. Review.

PMID:
26588682
18.

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.

Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizée G.

Cancer Immunol Res. 2015 Jun;3(6):602-9. doi: 10.1158/2326-6066.CIR-15-0030. Epub 2015 Mar 20.

19.

Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.

Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P.

Sarcoma. 2015;2015:547460. doi: 10.1155/2015/547460. Epub 2015 Jan 29.

20.

Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire.

Hunsucker SA, McGary CS, Vincent BG, Enyenihi AA, Waugh JP, McKinnon KP, Bixby LM, Ropp PA, Coghill JM, Wood WA, Gabriel DA, Sarantopoulos S, Shea TC, Serody JS, Alatrash G, Rodriguez-Cruz T, Lizée G, Buntzman AS, Frelinger JA, Glish GL, Armistead PM.

Cancer Immunol Res. 2015 Mar;3(3):228-35. doi: 10.1158/2326-6066.CIR-14-0001. Epub 2015 Jan 9.

21.

Inflammatory IL-1β-driven JNK activation in stage III melanoma.

Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA.

Pigment Cell Melanoma Res. 2015 Mar;28(2):236-9. doi: 10.1111/pcmr.12348. Epub 2015 Jan 12. No abstract available.

PMID:
25546243
22.

B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells.

Brown WS, Khalili JS, Rodriguez-Cruz TG, Lizee G, McIntyre BW.

J Biol Chem. 2014 Aug 15;289(33):23141-53. doi: 10.1074/jbc.M114.562918. Epub 2014 Jun 16.

23.

Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.

Li F, Guo Z, Lizée G, Yu H, Wang H, Si T.

Clin Chem Lab Med. 2014 Sep;52(9):1357-65. doi: 10.1515/cclm-2013-0878.

PMID:
24646790
24.

Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.

Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P.

J Immunother. 2013 May;36(4):276-86. doi: 10.1097/CJI.0b013e31829419f3.

25.

Forging a link between oncogenic signaling and immunosuppression in melanoma.

Khalili JS, Hwu P, Lizée G.

Oncoimmunology. 2013 Feb 1;2(2):e22745.

26.

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy.

Yang Y, Lizée G, Hwu P.

Oncoimmunology. 2013 Feb 1;2(2):e22730.

27.
28.

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, Lizée G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA.

Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10.

29.

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, Woodman SE, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2013 Jan 15;19(2):393-403. doi: 10.1158/1078-0432.CCR-12-1626. Epub 2012 Nov 30.

30.

A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.

Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, Molldrem JJ, Glish GL, Armistead PM, Alatrash G.

Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12.

31.

Harnessing the power of the immune system to target cancer.

Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P.

Annu Rev Med. 2013;64:71-90. doi: 10.1146/annurev-med-112311-083918. Epub 2012 Oct 22. Review.

PMID:
23092383
32.

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P.

Clin Cancer Res. 2012 Dec 15;18(24):6758-70. doi: 10.1158/1078-0432.CCR-12-1177. Epub 2012 Oct 2.

33.

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P.

Blood. 2012 Nov 29;120(23):4533-43. doi: 10.1182/blood-2012-02-407163. Epub 2012 Aug 30.

34.

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P.

Cancer Res. 2012 Oct 15;72(20):5209-18. doi: 10.1158/0008-5472.CAN-12-1187. Epub 2012 Aug 20.

35.

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.

Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE, Davies MA, Wargo JA, Hwu P, Lizée G.

Clin Cancer Res. 2012 Oct 1;18(19):5329-40. doi: 10.1158/1078-0432.CCR-12-1632. Epub 2012 Jul 31.

36.

Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.

Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE.

Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.

37.

The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, Wieder ED, Lizee G, Lu S, Molldrem JJ.

J Immunother. 2012 May;35(4):309-20. doi: 10.1097/CJI.0b013e31824b3b14.

38.

Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.

Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizée G, Zhou D, Overwijk WW, Hwu P.

J Immunother. 2012 Apr;35(3):276-82. doi: 10.1097/CJI.0b013e31824e7f43.

39.

BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.

Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P.

Clin Cancer Res. 2012 Apr 15;18(8):2326-35. doi: 10.1158/1078-0432.CCR-11-2515. Epub 2012 Feb 21. Erratum in: Clin Cancer Res. 2012 Jul 1;18(13):3715.

40.

Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG.

Clin Cancer Res. 2012 May 1;18(9):2465-77. doi: 10.1158/1078-0432.CCR-11-2034. Epub 2012 Feb 3.

41.

Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma.

Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA.

Mol Cancer Res. 2011 Nov;9(11):1537-50. doi: 10.1158/1541-7786.MCR-11-0279. Epub 2011 Sep 27.

42.

Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity.

Rodríguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W, Lizée G.

PLoS One. 2011;6(8):e22939. doi: 10.1371/journal.pone.0022939. Epub 2011 Aug 10.

43.

Antitumor activity mediated by CpG: the route of administration is critical.

Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P.

J Immunother. 2011 Apr;34(3):279-88. doi: 10.1097/CJI.0b013e31820d2a05.

PMID:
21389870
44.

Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.

Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G, Hwu P.

Clin Cancer Res. 2010 Nov 15;16(22):5458-68. doi: 10.1158/1078-0432.CCR-10-0712. Epub 2010 Oct 1.

45.

TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.

Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G.

J Immunother. 2010 May;33(4):371-81. doi: 10.1097/CJI.0b013e3181cd1180.

PMID:
20386469
46.

MHC class I endosomal and lysosomal trafficking coincides with exogenous antigen loading in dendritic cells.

Basha G, Lizée G, Reinicke AT, Seipp RP, Omilusik KD, Jefferies WA.

PLoS One. 2008 Sep 19;3(9):e3247. doi: 10.1371/journal.pone.0003247.

47.

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB.

Melanoma Res. 2008 Aug;18(4):241-5. doi: 10.1097/CMR.0b013e3283046146.

48.

Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.

Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P.

J Clin Invest. 2008 Mar;118(3):1165-75. doi: 10.1172/JCI33583.

49.

A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones.

Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, Neelapu SS.

J Immunol Methods. 2008 Feb 29;331(1-2):13-26. Epub 2007 Oct 9.

50.

Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.

Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ.

Vaccine. 2007 Nov 14;25(46):7955-61. Epub 2007 Sep 14.

PMID:
17933439

Supplemental Content

Support Center